featured
Sacituzumab Govitecan for Patients With Epithelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sacituzumab Govitecan, a Trop-2–Directed Antibody-Drug Conjugate, for Patients With Epithelial Cancer: Final Safety and Efficacy Results From the Phase 1/2 IMMU-132-01 Basket Trial
Ann. Oncol 2021 Mar 16;[EPub Ahead of Print], A Bardia, WA Messersmith, EA Kio, JD Berlin, L Vahdat, GA Masters, R Moroose, AD Santin, K Kalinsky, V Picozzi, J O'Shaughnessy, JE Gray, T Komiya, JM Lang, JC Chang, A Starodub, DM Goldenberg, RM Sharkey, P Maliakal, Q Hong, WA Wegener, T Goswami, AJ OceanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.